OR WAIT 15 SECS
August 11, 2015.
The global market for growth hormone deficiency (GHD) treatment will rise in value from $1.26 billion in 2014 to reach approximately $1.88 billion by 2024, according to research and consulting firm GlobalData.
The company’s latest report states that the increase, which will occur across the seven major countries of the US, France, Germany, Italy, Spain, UK, and Japan, will be primarily driven by the launch of long-acting growth hormone biobetters, which are expected to begin entering the market in 2017.
GlobalData forecasts that the global sales for the daily recombinant growth hormone drugs will decline at a negative CAGR of 5.95%, from $1.26 billion in 2014 to $684 million by 2024. However, global sales for the long-acting growth hormone drugs are forecast to reach around $1.2 billion by the end of the forecast period.
For more information, see the report: OpportunityAnalyzer: Growth Hormone Deficiency – Opportunity Analysis and Forecast to 2024